ReviewDiagnostics (Basel, Switzerland)2023

From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC).

Laura Fabbri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.